CD274 and vulva cancer: In summary, the best available protocol for adding ICIs to conventional treatments for HPV-associated vulvar cancer includes using pembrolizumab as a second-line therapy for PD-L1-positive advanced or recurrent/metastatic disease, as recommended by the NCCN guidelines, and considering combination strategies with cisplatin and radiation therapy for locally advanced or unresectable cases [66].